ArticleCureus2025
Using Radiofrequency Echographic Multi-spectrometry in the Follow-Up of Patients With Axial Spondyloarthritis and Psoriatic Arthritis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSpondyloarthritis comprises a group of diseases with similar clinical, paraclinical, and imagistic findings. Another common element in this group is its association with osteoporosis and increased bone fragility, which can have dire consequences on the quality of life of these patients. MATERIALS AND
methodsA prospective study was performed in order to evaluate the bone density and fragility parameters offered by radiofrequency echographic multi-spectrometry (REMS). A group of 70 patients, 49 with axial spondyloarthritis and 21 with psoriatic arthritis, were evaluated using REMS and followed up at one year to see if there is any modification of bone mineral density (BMD), T scores, and of the fragility score (FS) under treatment.
resultsBoth groups showed slightly improved values for BMD and T-scores, with significant improvement for BMD in both groups with p<0.001, with an maximum increase of 0.03 g/cm
conclusionREMS is a method that need to be further studied in axial spondyloarthritis and psoriatic arthritis in order to describe it's usefulness in these specific pathologies. FS can be a useful tool in assessing bone health under different treatment conditions. Although improvement was seen in all markers under biological treatment and combined treatment, the most favourable results were observed in patients under biological disease-modifying antirheumatic drug (bDMARD) and combined conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) and bDMARD therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.